Skip to content
You are now leaving to visit

Ionis Reports Fourth Quarter and Full Year 2017 Financial Results

SPINRAZA launch one of the most successful in rare disease history FY 2017 GAAP operating income of $25M; FY 2017 pro forma operating income of $111M 2017 year-end cash over $1B Mid-2018 launches planned for inotersen and volanesorsen Conference call and webcast today, February 27, 2018, at 11:30